{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T15:02:27Z","timestamp":1778857347560,"version":"3.51.4"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,11,28]],"date-time":"2022-11-28T00:00:00Z","timestamp":1669593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,11,28]],"date-time":"2022-11-28T00:00:00Z","timestamp":1669593600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1007\/s00277-022-05049-6","type":"journal-article","created":{"date-parts":[[2022,11,28]],"date-time":"2022-11-28T06:05:06Z","timestamp":1669615506000},"page":"457-459","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Real-world experience and considerations on concomitant caplacizumab and anticoagulation in thrombotic thrombocytopenic purpura"],"prefix":"10.1007","volume":"102","author":[{"given":"Benson","family":"Meek","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nuti","family":"Desai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donald C.","family":"Moore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thuy","family":"Tran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary Ann","family":"Knovich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0901-4866","authenticated-orcid":false,"given":"Justin","family":"Arnall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,11,28]]},"reference":[{"issue":"15","key":"5049_CR1","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1093\/ajhp\/zxaa151","volume":"77","author":"AL Hollifield","year":"2020","unstructured":"Hollifield AL, Arnall JR, Moore DC (2020) Caplacizumab: an anti-von Willebrand factor antibody for the treatment of thrombotic thrombocytopenic purpura. Am J Health Syst Pharm 77(15):1201\u20131207","journal-title":"Am J Health Syst Pharm"},{"key":"5049_CR2","doi-asserted-by":"publisher","first-page":"2486","DOI":"10.1111\/jth.15006","volume":"18","author":"XL Zheng","year":"2020","unstructured":"Zheng XL, Vesely SK, Cataland SR et al (2020) ISTH guidelines for the diagnosis of thrombotic thrombocytopenic purpura. J Thromb Haemost 18:2486\u20132495. https:\/\/doi.org\/10.1111\/jth.15006","journal-title":"J Thromb Haemost"},{"key":"5049_CR3","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1080\/17512433.2021.1944102","volume":"14","author":"T Elverdi","year":"2021","unstructured":"Elverdi T et al (2021) Do patients with immune-mediated thrombotic thrombocytopenic purpura receiving caplacizumab need antithrombotic therapy? Expert Rev Clin Pharmacol 14:1183\u20131188","journal-title":"Expert Rev Clin Pharmacol"},{"key":"5049_CR4","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1056\/JENMoa1505533","volume":"374","author":"F Peyvandi","year":"2016","unstructured":"Peyvandi F et al (2016) Caplacizumab for acquired thrombotic thrombocytopenic purpura. N Engl J Med 374:511\u2013522. https:\/\/doi.org\/10.1056\/JENMoa1505533","journal-title":"N Engl J Med"},{"key":"5049_CR5","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1056\/NEJMoa1806311","volume":"380","author":"M Scully","year":"2019","unstructured":"Scully M et al (2019) Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura. N Engl J Med 380:335\u2013346. https:\/\/doi.org\/10.1056\/NEJMoa1806311","journal-title":"N Engl J Med"},{"key":"5049_CR6","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1111\/jth.13716","volume":"15","author":"F Peyvandi","year":"2017","unstructured":"Peyvandi F et al (2017) Caplacizumab reduces the frequency of major thromboembolic events, exacerbations, and death in patients with acquired thrombotic thrombocytopenic purpura. J Thromb Haemost 15:1448\u20131452. https:\/\/doi.org\/10.1111\/jth.13716","journal-title":"J Thromb Haemost"},{"key":"5049_CR7","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1182\/blood.2020007599","volume":"137","author":"T Dutt","year":"2021","unstructured":"Dutt T et al (2021) Real-world experience with caplacizumab in the management of acute TTP. Blood 137:1731\u20131740. https:\/\/doi.org\/10.1182\/blood.2020007599","journal-title":"Blood"},{"key":"5049_CR8","doi-asserted-by":"publisher","first-page":"2870","DOI":"10.1111\/jth.15027","volume":"18","author":"B Tse","year":"2020","unstructured":"Tse B et al (2020) Describing the point prevalence and characteristics of venous thromboembolism in patients with thrombotic thrombocytopenic purpura. J Thromb Haemost 18:2870\u20132877. https:\/\/doi.org\/10.1111\/jth.15027","journal-title":"J Thromb Haemost"},{"key":"5049_CR9","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1111\/jth.15194","volume":"19","author":"A Picod","year":"2021","unstructured":"Picod A, Veyradier A, Coppo P (2021) Should all patients with immune-mediated thrombotic thrombocytopenic purpura receive caplacizumab? J Thromb Haemost 19:58\u201367. https:\/\/doi.org\/10.1111\/jth.15194","journal-title":"J Thromb Haemost"},{"key":"5049_CR10","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1016\/j.revmed.2020.06.014","volume":"41","author":"Y Benhamou","year":"2020","unstructured":"Benhamou Y et al (2020) Venous thrombo-embolism during immune-mediated thrombotic thrombocytopenic purpura is prevalent in patients with a prolonged treatment with therapeutic plasma exchange. La Revue de Medicine Intern 41:809\u2013813. https:\/\/doi.org\/10.1016\/j.revmed.2020.06.014","journal-title":"La Revue de Medicine Intern"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-022-05049-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-022-05049-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-022-05049-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,31]],"date-time":"2023-01-31T09:06:42Z","timestamp":1675156002000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-022-05049-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,28]]},"references-count":10,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["5049"],"URL":"https:\/\/doi.org\/10.1007\/s00277-022-05049-6","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,28]]},"assertion":[{"value":"4 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 November 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 November 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"N\/A. This is a case report of therapy selection and response to therapy outside of a clinical trial. This article does not contain any studies with human participants performed by any of the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research involving human participants and\/or animals"}},{"value":"N\/A. Institutional review board reviewed, and patient consent identified as not required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"Donald Moore has served on advisor boards for Pfizer, AstraZeneca, and Janssen. Justin Arnall is supported by Novo Nordisk (Hemophilia) Speaker\u2019s Bureau, CTI Biopharma Advisory Board. The rest of the authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}